A Study of Pembrolizumab in Relapsed or Refractory Classical Hodgkin’s Lymphoma or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in